DE69531148D1 - Bibliotheken aus polyklonalen antikörpern - Google Patents

Bibliotheken aus polyklonalen antikörpern

Info

Publication number
DE69531148D1
DE69531148D1 DE69531148T DE69531148T DE69531148D1 DE 69531148 D1 DE69531148 D1 DE 69531148D1 DE 69531148 T DE69531148 T DE 69531148T DE 69531148 T DE69531148 T DE 69531148T DE 69531148 D1 DE69531148 D1 DE 69531148D1
Authority
DE
Germany
Prior art keywords
libraries
disease
patient
variable regions
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531148T
Other languages
English (en)
Other versions
DE69531148T2 (de
Inventor
Jacqueline Sharon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of DE69531148D1 publication Critical patent/DE69531148D1/de
Application granted granted Critical
Publication of DE69531148T2 publication Critical patent/DE69531148T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
DE69531148T 1994-01-31 1995-01-27 Bibliotheken aus polyklonalen antikörpern Expired - Lifetime DE69531148T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18936094A 1994-01-31 1994-01-31
US189360 1994-01-31
PCT/US1995/001197 WO1995020401A1 (en) 1994-01-31 1995-01-27 Polyclonal antibody libraries

Publications (2)

Publication Number Publication Date
DE69531148D1 true DE69531148D1 (de) 2003-07-31
DE69531148T2 DE69531148T2 (de) 2004-04-29

Family

ID=22696993

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69531148T Expired - Lifetime DE69531148T2 (de) 1994-01-31 1995-01-27 Bibliotheken aus polyklonalen antikörpern
DE69534347T Expired - Lifetime DE69534347T2 (de) 1994-01-31 1995-01-27 Bibliotheken aus Polyklonalen Antikörpern

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69534347T Expired - Lifetime DE69534347T2 (de) 1994-01-31 1995-01-27 Bibliotheken aus Polyklonalen Antikörpern

Country Status (9)

Country Link
US (2) US5789208A (de)
EP (2) EP0744958B1 (de)
AT (2) ATE300610T1 (de)
AU (1) AU1736495A (de)
DE (2) DE69531148T2 (de)
DK (2) DK1231268T3 (de)
ES (2) ES2247204T3 (de)
PT (2) PT1231268E (de)
WO (1) WO1995020401A1 (de)

Families Citing this family (620)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036092A1 (en) * 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5866344A (en) * 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
KR100566859B1 (ko) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Ｒｎａ-단백질 융합물을 이용한 단백질의 선별
US6555310B1 (en) 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU8755798A (en) * 1997-04-04 1998-11-13 Biosite Diagnostics Incorporated Polyvalent and polyclonal libraries
EP1025256A2 (de) * 1997-10-09 2000-08-09 Ixsys, Incorporated Verfahren zur identifizierung von mit rezeptoren gebundenen ligenden
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6100063A (en) * 1998-02-12 2000-08-08 Novo Nordisk A/S Procaryotic cell comprising at least two copies of a gene
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
IL138668A0 (en) * 1998-04-03 2001-10-31 Phylos Inc Addressable protein arrays
CA2334946A1 (en) * 1998-08-17 2000-02-24 Phylos, Inc. Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation
JP4278872B2 (ja) 1998-08-17 2009-06-17 フィロス インク． 蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定
ATE354675T1 (de) * 1998-12-02 2007-03-15 Adnexus Therapeutics Inc Dna-protein fusionen sowie anwendungen derselben
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
CN101081305B (zh) * 1999-03-16 2010-11-10 花王株式会社 液体除臭剂
DE60020143T2 (de) 1999-03-31 2006-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Centers for Disease Control and Prevention, Office of Technology Transfer, Atlanta Typisierung von humanen enteroviren
US6623926B1 (en) 1999-06-01 2003-09-23 Phylos, Inc. Methods for producing 5′-nucleic acid-protein conjugates
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US20070111259A1 (en) * 1999-10-02 2007-05-17 Medarex, Inc. Human antibodies
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US6657048B2 (en) 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
WO2001053539A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
DK1283720T3 (da) * 2000-05-26 2007-08-13 Symphogen As Rekombinante eller rensede polyklonale antistoffer til behandling af allergi
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
PT1360208E (pt) * 2000-11-08 2008-06-11 Arius Res Inc Anticorpos anti cancerígenos individualizados
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
EP2354149B1 (de) 2000-12-12 2017-08-30 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
AU2002250064B2 (en) * 2001-02-13 2008-01-17 University Of Florida Research Foundation, Inc. A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
ES2328796T3 (es) 2001-03-14 2009-11-18 Myriad Genetics, Inc. Interaccion tsg101-gag y uso de la misma.
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
AU2002332595A1 (en) * 2001-08-22 2003-03-10 Steven Kessler Methods for screening antibody-producing cells on heterogenous antigen substrates
US20060073095A1 (en) * 2001-08-22 2006-04-06 Steven Kessler Methods for screening antibody-producing cells on heterogeneous antigen substrates
WO2003028625A2 (en) * 2001-08-22 2003-04-10 Steven Kessler Methods for screening monoclonal antibodies on heterogeneous antigen substrates
US6696271B2 (en) * 2001-08-23 2004-02-24 The Regents Of The University Of California Frozen tissue microarray technology for analysis of RNA, DNA, and proteins
US20050048566A1 (en) * 2001-08-27 2005-03-03 Delisi Charles Apparatus, composition and method for proteome profiling
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
US20040005709A1 (en) * 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
AU2002226211A1 (en) * 2001-12-21 2003-07-15 Arius Research, Inc. Individualized anti-cancer antibodies
EP1757305A3 (de) * 2001-12-21 2007-03-14 Arius Research, Inc. Individualisierte Antikörper gegen Krebs
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
CN1186445C (zh) * 2002-03-15 2005-01-26 陈志南 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
US7012100B1 (en) * 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
WO2003106639A2 (en) * 2002-06-14 2003-12-24 Dyax Corporation Recombination of nucleic acid library members
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
WO2004027028A2 (en) * 2002-09-18 2004-04-01 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for detection of an antigen on a cell and in a biological mixture
EP2298806A1 (de) 2002-10-16 2011-03-23 Purdue Pharma L.P. Antikörper, die an zellassoziiertes CA 125/0722P binden, und Verfahren zu deren Anwendung
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
EP1762617A1 (de) * 2003-01-07 2007-03-14 Symphogen A/S Verfahren zur Herstellung von rekombinanten polyklonalen Proteinen
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CN100383244C (zh) * 2003-01-07 2008-04-23 西福根有限公司 用于生产重组多克隆蛋白质的方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2347959T3 (es) 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
US7785829B2 (en) 2003-03-19 2010-08-31 Biogen Idec Ma, Inc. Nogo receptor binding protein
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP2374819B1 (de) 2003-05-12 2017-03-22 Helion Biotech ApS Antikörper gegen MASP-2
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP1644408A1 (de) 2003-07-15 2006-04-12 Barros Research Institute Eimeria tenella-antigen zur immuntherapie von kokzidiose
WO2005014795A2 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1673465A4 (de) * 2003-09-29 2008-04-30 Biosite Inc Verfahren und zusammensetzungen zur sepsisdiagnose
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
SI1983000T1 (sl) 2003-11-21 2015-12-31 Ucb Biopharma Sprl Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
US7884054B2 (en) 2003-12-22 2011-02-08 Amgen Inc. Methods for identifying functional antibodies
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
EP1786463A4 (de) 2004-03-26 2009-05-20 Human Genome Sciences Inc Antikörper gegen nogo-rezeptor
US20050260710A1 (en) * 2004-03-31 2005-11-24 Sekisui Chemical Co. Ltd. Methods for producing recombinant polyclonal immunoglobulins
EP2207033B1 (de) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neuralproteine als Biomarker für Verletzungen des Nervensystems und anderen neuralen Störungen
CA2562764A1 (en) 2004-04-23 2005-11-03 Richard Kroczek Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
BRPI0512500A (pt) 2004-06-24 2008-03-11 Biogen Idec Inc tratamento ou condições envolvendo desmielinação
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
WO2006007853A2 (en) * 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
BRPI0513706A (pt) * 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
EP1791975A4 (de) * 2004-08-05 2007-11-07 Biosite Inc Zusammensetzungen und verfahren für phagen-display von polypeptiden
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7833725B2 (en) * 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
CN101495498B (zh) 2005-02-07 2013-09-18 基因信息公司 轻度骨关节炎生物标志物及其用途
JP5651285B2 (ja) 2005-02-15 2015-01-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
EP1858545A2 (de) 2005-03-04 2007-11-28 Curedm Inc. Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
US7618809B2 (en) 2005-03-23 2009-11-17 Gebing Ronald A Microarrayer with coaxial multiple punches
EP1707628B1 (de) * 2005-03-30 2009-11-11 Sekisui Chemical Co., Ltd. Verfahren zur Produktion von rekombinanten polyklonalen Immunglobulinen
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
EP1920057A4 (de) 2005-08-03 2009-03-18 Grains Res & Dev Corp Polysaccharid-synthasen
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500359A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
ATE546160T1 (de) 2005-09-14 2012-03-15 Ucb Pharma Sa Antikörper-kammpolymer-konjugat
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
CA2626604A1 (en) 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
CA2628451A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
ES2409835T3 (es) 2005-11-28 2013-06-28 Zymogenetics, Inc. Antagonistas de IL-21
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
EP1965827B1 (de) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
UA96141C2 (ru) 2005-12-09 2011-10-10 Юсиби Фарма, С.А. Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP1981902B1 (de) 2006-01-27 2015-07-29 Biogen MA Inc. Nogo-rezeptorantagonisten
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
KR20080110800A (ko) 2006-03-15 2008-12-19 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
EP2037961B1 (de) 2006-06-14 2015-11-11 MacroGenics, Inc. Verfahren zur behandlung von autoimmunerkrankungen anhand von monoklonalen antikörpern mit verminderter toxizität
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
JP4546578B2 (ja) 2006-07-05 2010-09-15 カタリスト・バイオサイエンシーズ・インコーポレイテッド プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
EP2064243A2 (de) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistische lichtspezifische menschliche monoklonale antikörper
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
PT2061810E (pt) 2006-09-05 2015-02-05 Alexion Pharma Inc Métodos e composições para o tratamento de neuropatias mediadas por anticorpos
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
EP2407548A1 (de) 2006-10-16 2012-01-18 MedImmune, LLC Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
MX2009004221A (es) * 2006-10-20 2009-09-10 Univ Arizona State Cianobacterias modificadas.
EA200970469A1 (ru) 2006-11-09 2010-04-30 АйАрЭм ЭлЭлСи Антитела-агонисты рецептора trkb и их применение
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
DK2068887T3 (da) 2007-01-09 2014-05-19 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2121745A2 (de) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteine
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ATE521704T1 (de) 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
DK2125894T3 (en) 2007-03-22 2019-03-18 Biogen Ma Inc BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
ES2540807T3 (es) 2007-05-04 2015-07-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
NZ599278A (en) 2007-05-14 2013-12-20 Medimmune Llc Methods of reducing eosinophil levels
BRPI0812400A2 (pt) 2007-06-05 2014-10-29 Univ Yale Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
EP3424951A1 (de) 2007-06-21 2019-01-09 MacroGenics, Inc. Kovalente diabodies und deren verwendung
MY165889A (en) 2007-08-30 2018-05-18 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
EP3072963B1 (de) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
ES2557352T3 (es) 2007-11-05 2016-01-25 Medimmune, Llc Métodos de tratamiento de la esclerodermia
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
CA2711771C (en) 2008-01-11 2017-01-24 Gene Techno Science Co., Ltd. Humanized anti-.alpha.9 integrin antibodies and the uses thereof
WO2009092011A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
CA2713055C (en) * 2008-01-25 2018-03-13 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
KR101666229B1 (ko) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
JP6014706B2 (ja) * 2008-02-14 2016-10-25 株式会社イーベック ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
EP3045475B1 (de) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
US8802093B2 (en) 2008-04-02 2014-08-12 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
AU2009234267B2 (en) 2008-04-11 2014-10-30 Seagen Inc. Detection and treatment of pancreatic, ovarian and other cancers
CA2722348A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2009131256A1 (en) 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
EP2282769A4 (de) 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009136382A2 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010033237A2 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
US20100093563A1 (en) * 2008-09-22 2010-04-15 Robert Anthony Williamson Methods and vectors for display of molecules and displayed molecules and collections
AU2009308422B2 (en) 2008-10-24 2017-01-05 The Government of the United States of America as represented by The Secretary, Department of Health and Human Services, Center for Disease Control and Prevention Human Ebola virus species and compositions and methods thereof
WO2010054289A1 (en) * 2008-11-10 2010-05-14 Kids Ii, Inc. Electromagnetic children's bouncer
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
EP2370092A1 (de) 2008-12-03 2011-10-05 Research Development Foundation Modulierung von olfml-3-vermittelter angiogenese
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
US20130122052A1 (en) 2009-01-20 2013-05-16 Homayoun H. Zadeh Antibody mediated osseous regeneration
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2744236C (en) 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
LT2398498T (lt) 2009-02-17 2019-01-10 Ucb Biopharma Sprl Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
PE20121094A1 (es) 2009-03-05 2012-09-13 Abbvie Inc Proteinas de union a il-17
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
EP2406285B1 (de) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Erzeugung, expression und charakterisierung des humanisierten monoklonalen antikörpers k33n
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
EP2470568A2 (de) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutische dll4-bindende proteine
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
EP2493926B1 (de) 2009-10-27 2020-03-11 UCB Biopharma SRL Funktionelle modifizierung von nav1.7-antikörpern
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
EP2499491B1 (de) 2009-11-11 2015-04-01 Gentian AS Immunassay zur untersuchung von assoziierten analyten unterschiedlichen ursprungs
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
EP2550297B1 (de) 2010-03-25 2019-01-23 UCB Biopharma SPRL Mit disulfid stabilisierte dvd-lg-moleküle
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
ES2552954T3 (es) 2010-04-30 2015-12-03 Alexion Pharmaceuticals, Inc. Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
UY33386A (es) 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
EP2580239A1 (de) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
PL3333188T3 (pl) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Przeciwciała anty-ngf i ich zastosowanie
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2614080A1 (de) 2010-09-10 2013-07-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Phosphoryliertes twist1 und metastasen
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
KR101941514B1 (ko) 2010-12-22 2019-01-23 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 개선된 반감기를 가지는 변형된 항체
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
CN103384682B (zh) 2011-01-14 2017-04-12 Ucb医药有限公司 结合il‑17a和il‑17f的抗体分子
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
MX347818B (es) 2011-05-21 2017-05-15 Macrogenics Inc Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
EP2714094B1 (de) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. An einen anti-nucleolin-wirkstoff konjugierte nanopartikel
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
MX349886B (es) 2011-06-10 2017-08-17 Medimmune Llc Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
SI2726094T1 (sl) 2011-06-28 2017-04-26 Oxford Biotherapeutics Ltd Terapevtski in diagnostični cilj
CA2840537C (en) 2011-06-28 2021-12-14 Oxford Biotherapeutics Ltd. Antibodies to adp-ribosyl cyclase 2
KR20140061403A (ko) 2011-07-13 2014-05-21 애브비 인코포레이티드 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA2842971C (en) 2011-08-05 2019-11-12 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
SG10201606158TA (en) 2011-08-05 2016-09-29 Regeneron Pharma Humanized universal light chain mice
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
AU2012306341B2 (en) 2011-09-09 2017-08-31 Cambridge Enterprise Limited Anti-Siglec-15 antibodies and uses thereof
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
WO2013068571A1 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
ES2725569T3 (es) 2012-02-10 2019-09-24 Seattle Genetics Inc Diagnóstico y tratamiento de cánceres que expresan CD30
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3196214B1 (de) 2012-02-15 2019-07-31 Novo Nordisk A/S Antikörper, die den auslösenden rezeptor binden und blockieren, der auf myeloid-zellen-1 (trem-1) exprimiert ist
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CA2866185C (en) 2012-03-23 2021-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
BR112014028306A2 (pt) 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
EP2867674B1 (de) 2012-06-28 2018-10-10 UCB Biopharma SPRL Verfahren zur identifikation von verbindungen von therapeutischem interesse
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
EP2869818A1 (de) 2012-07-06 2015-05-13 Novartis AG Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
KR102229873B1 (ko) 2012-10-12 2021-03-19 더 브리검 앤드 우먼즈 하스피털, 인크. 면역 반응의 향상
DK2912064T3 (da) 2012-10-24 2019-07-22 Res Found Dev Jam-c-antistoffer og fremgangsmåder til behandling af cancer
TW202210507A (zh) 2012-11-01 2022-03-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
BR112015014621A2 (pt) 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
SG11201507432XA (en) 2013-03-15 2015-10-29 Abbvie Inc Antibody drug conjugate (adc) purification
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
PT2968588T (pt) 2013-03-15 2019-05-08 Abbvie Inc Formulações de conjugado de fármaco-anticorpo anti-egfr
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
EP3063317B1 (de) 2013-10-28 2020-06-03 DOTS Technology Corp. Allergennachweis
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
KR102352573B1 (ko) 2014-04-04 2022-01-18 바이오노믹스 인코포레이티드 Ｌｇｒ５에 결합하는 인간화된 항체들
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
CA2950602C (en) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
EP3154579A1 (de) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research Neue behandlung gegen das influenzavirus
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
EP3164129A1 (de) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP6738316B2 (ja) 2014-07-17 2020-08-12 ノヴォ ノルディスク アクティーゼルスカブ 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
EP3197557A1 (de) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats und brustrkrebs
KR20230153495A (ko) 2014-10-01 2023-11-06 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
US20170304460A1 (en) 2014-10-01 2017-10-26 Medimmune, Llc Method of conjugating a polypeptide
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20170087500A (ko) 2014-12-11 2017-07-28 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
JP2018518152A (ja) 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア 充実性腫瘍を処置するためのｌｈｒに指向されたｃａｒ ｔ細胞治療
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016172769A1 (en) 2015-04-29 2016-11-03 University Of South Australia Compositions and methods for administering antibodies
US11136613B2 (en) 2015-04-30 2021-10-05 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
EP3291839A1 (de) 2015-05-05 2018-03-14 The University of Louisville Research Foundation, Inc. Antinukleolinmittelkonjugierte nanopartikel als radiosensibilisatoren und mrt- und/oder röntgenkontrastmittel
WO2016179518A2 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
CN113940996A (zh) 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
EP3303395B1 (de) 2015-05-29 2019-12-11 AbbVie Inc. Anti-cd40-antikörper und verwendungen davon
PL3303394T3 (pl) 2015-05-29 2020-11-16 Agenus Inc. Przeciwciała anty-ctla-4 i sposoby ich zastosowania
JP7010473B2 (ja) 2015-06-04 2022-02-10 ユニバーシティ オブ サザン カリフォルニア Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
BR112018003186A2 (pt) 2015-09-01 2018-09-25 Agenus Inc. anticorpos anti-pd-1 e seus métodos de uso
EP3569244A1 (de) 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3-gerichtete car-zellen zur immuntherapie
RU2754683C2 (ru) 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US10829562B2 (en) 2015-12-10 2020-11-10 Katholieke Universiteit Leuven Haemorrhagic disorder due to ventricular assist device
CA3011734A1 (en) 2016-01-27 2017-08-03 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
CN109071642B (zh) 2016-02-26 2022-08-09 德克萨斯大学体系董事会 连接蛋白(Cx)43半通道结合抗体及其用途
KR102632796B1 (ko) 2016-03-10 2024-02-02 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
MX2018011939A (es) 2016-03-29 2019-05-20 Stcube Inc Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
EP3436480A4 (de) 2016-03-30 2019-11-27 Musc Foundation for Research Development Verfahren zur behandlung und diagnose von krebs durch targeting von glycoprotein a repetitions predominant (garp) und zur effektiven immuntherapie allein oder in kombination
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3519824A1 (de) 2016-10-03 2019-08-07 Abbott Laboratories Verbesserte verfahren zur beurteilung des uch-l1-status in patientenproben
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
CA3041843A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3042989A1 (en) 2016-11-07 2018-05-11 Junho Chung Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3541847A4 (de) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
EP3589319A4 (de) 2017-03-03 2021-07-14 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
JP7344797B2 (ja) 2017-04-15 2023-09-14 アボット・ラボラトリーズ 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
PL3618863T3 (pl) 2017-05-01 2023-11-06 Agenus Inc. Przeciwciała anty- tigit i sposoby ich zastosowania
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
US10849548B2 (en) 2017-05-30 2020-12-01 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
EP3652209A2 (de) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon
RS61817B1 (sr) 2017-07-14 2021-06-30 Immatics Biotechnologies Gmbh Poboljšani polipeptidni molekul sa dvojnom specifičnošću
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US11306144B2 (en) 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
GB2581619A (en) 2017-09-15 2020-08-26 Univ California Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
CN109535257B (zh) 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
IL310960A (en) 2017-09-22 2024-04-01 Wuxi Biologics Ireland Ltd New bispecific polypeptide complexes
CN111630069A (zh) 2017-10-13 2020-09-04 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
AU2018371271A1 (en) 2017-11-27 2020-06-11 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
JP7379165B2 (ja) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
CA3067057A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
JP2021516051A (ja) 2018-03-02 2021-07-01 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体及びその使用方法
EP3765499A1 (de) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf-antikörper und verfahren dafür
CA3092635A1 (en) 2018-03-14 2019-09-19 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof
BR112020018918A2 (pt) 2018-03-22 2021-01-05 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
EP3784274A1 (de) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
EP3806898A1 (de) 2018-06-18 2021-04-21 UCB Biopharma SRL Gremlin-1-antagonist zur vorbeugung und behandlung von krebs
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
EP3824287A1 (de) 2018-07-20 2021-05-26 Pierre Fabre Médicament Rezeptor für vista
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
CN113166269A (zh) 2018-11-13 2021-07-23 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
TW202031684A (zh) 2018-12-20 2020-09-01 日商協和麒麟股份有限公司 Fn14抗體及其用途
CA3127072A1 (en) 2019-01-16 2020-07-23 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
US11242407B2 (en) 2019-02-26 2022-02-08 Inspirna, Inc. High-affinity anti-MERTK antibodies and uses thereof
JP2022524215A (ja) 2019-03-28 2022-04-28 ダニスコ・ユーエス・インク 改変抗体
AU2020329217A1 (en) 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
EP4025606A1 (de) 2019-09-04 2022-07-13 Y-Biologics Inc. Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
JP2022548484A (ja) 2019-09-16 2022-11-21 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ３９抗体の組成物及び方法
TW202128752A (zh) 2019-09-25 2021-08-01 美商表面腫瘤學公司 抗ｉｌ﹘２７抗體及其用途
EP4041767A1 (de) 2019-09-26 2022-08-17 StCube & Co. Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
MX2022008341A (es) 2020-01-06 2022-08-10 Vaccinex Inc Anticuerpos anti-ccr8 y usos de estos.
EP4100435A1 (de) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Tat-peptidbindende proteine und ihre verwendungen
WO2021160266A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
US20230096030A1 (en) 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103608A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd137
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
EP4103612A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
AU2021224572A1 (en) 2020-02-18 2022-08-25 Alector Llc Pilra antibodies and methods of use thereof
US20230235073A1 (en) 2020-03-06 2023-07-27 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
CN115485295A (zh) 2020-03-10 2022-12-16 麻省理工学院 NPM1c阳性癌症的免疫疗法的组合物和方法
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
AR122111A1 (es) 2020-05-17 2022-08-17 Astrazeneca Uk Ltd ANTICUERPOS CONTRA EL SARS-CoV-2 Y MÉTODOS DE SELECCIÓN Y USO DE LOS MISMOS
WO2022018040A2 (en) 2020-07-20 2022-01-27 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
KR20230042301A (ko) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
MX2023002001A (es) 2020-08-18 2023-03-21 Cephalon Llc Anticuerpos anti-par-2 y metodos de uso de los mismos.
EP4229081A1 (de) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
EP4229086A1 (de) 2020-10-15 2023-08-23 UCB Biopharma SRL Bindungsmoleküle, die cd45 multimerisieren
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
MX2023006426A (es) 2020-12-01 2023-07-17 Aptevo Res And Development Llc Antígenos asociados a tumores y proteínas de unión a cd3 y composiciones y métodos relacionados.
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
EP4277664A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antikörper-pyrrolobenzodiazepinderivat-konjugat
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
TW202309071A (zh) 2021-05-05 2023-03-01 德商英麥提克生物技術股份有限公司 特異性結合ｐｒａｍｅ之抗原結合蛋白
JP2024516970A (ja) 2021-05-07 2024-04-18 サーフィス オンコロジー， エルエルシー 抗ｉｌ－２７抗体及びその使用
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4348263A1 (de) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Verfahren zum nachweis von cm-tma-biomarkern
AU2022293999A1 (en) 2021-06-14 2023-11-30 argenx BV Anti-il-9 antibodies and methods of use thereof
BR112023026199A2 (pt) 2021-06-14 2024-03-05 Abbott Lab Métodos para diagnosticar ou auxiliar no diagnóstico de lesão cerebral causada por energia acústica, energia eletromagnética, onda de sobrepressurização e/ou rajada de vento
KR20240025597A (ko) 2021-06-29 2024-02-27 씨젠 인크. 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
WO2023007472A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
ATE114723T1 (de) * 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2919890B2 (ja) * 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE59109273D1 (de) * 1990-02-01 2010-01-07 Siemens Healthcare Diagnostics Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) * 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
WO1992015678A1 (en) * 1991-03-01 1992-09-17 Stratagene Pcr generated dicistronic dna molecules for producing antibodies
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
US5955341A (en) 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DK1471142T3 (da) * 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
DE69218947T2 (de) 1991-07-29 1997-07-17 Dow Chemical Co Gehärtete cermets und verfahren zur herstellung von gehärteten cermets
CA2114950A1 (en) * 1991-08-10 1993-02-11 Michael J. Embleton Treatment of cell populations
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH08502645A (ja) 1992-09-04 1996-03-26 ザ スクリップス リサーチ インスティテュート 表面レセプター及び表面異種タンパク質を同時発現するファージミド
WO1994006920A1 (en) 1992-09-22 1994-03-31 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DE69332744T2 (de) 1992-09-30 2004-01-15 Scripps Research Inst Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
EP0672142B1 (de) 1992-12-04 2001-02-28 Medical Research Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US6214613B1 (en) * 1993-12-03 2001-04-10 Ashai Kasei Kogyo Kabushiki Kaisha Expression screening vector
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
EP0932698A1 (de) 1996-03-26 1999-08-04 Lynx Therapeutics, Inc. Oligonukleotide zusammenstellungen zur behandlung von menschlichem melanom
US5981199A (en) 1996-06-14 1999-11-09 Boehringer Mannheim Corporation Method for measuring antigen concentration
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries

Also Published As

Publication number Publication date
PT1231268E (pt) 2005-11-30
DK0744958T3 (da) 2003-10-20
DK1231268T3 (da) 2005-11-21
ES2201097T3 (es) 2004-03-16
EP0744958B1 (de) 2003-06-25
AU1736495A (en) 1995-08-15
DE69534347D1 (de) 2005-09-01
DE69534347T2 (de) 2006-05-24
WO1995020401A1 (en) 1995-08-03
EP1231268A2 (de) 2002-08-14
EP1231268A3 (de) 2002-08-21
ATE243745T1 (de) 2003-07-15
US6335163B1 (en) 2002-01-01
US5789208A (en) 1998-08-04
DE69531148T2 (de) 2004-04-29
EP0744958A1 (de) 1996-12-04
EP1231268B1 (de) 2005-07-27
ES2247204T3 (es) 2006-03-01
PT744958E (pt) 2003-11-28
EP0744958A4 (de) 1997-07-30
ATE300610T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
DE69531148D1 (de) Bibliotheken aus polyklonalen antikörpern
Ishizaka et al. Biologic activities of aggregated γ-globulin: VIII. Aggregated immunoglobulins of different classes
Rockey et al. Beta-2A aglobulinemia in two healthy men
Lehmann et al. Local immune response in experimental pyelonephritis
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
DE3887675T2 (de) Antikörper.
ATE348843T1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
DE69028388D1 (de) Monoklonaler antikörper gegen ein neues humanes tumor assoziiertes antigen
DK0712307T3 (da) Fremgangsmåder til B-cellepopulationsregulering
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
JPH0611235B2 (ja) モノクロ−ナル抗体
Chiba et al. Virus excretion and antibody response in saliva in natural mumps
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
Schneiderman et al. Activation of the alternative pathway of complement by twelve different rabbit-mouse chimeric transfectoma IgA isotypes.
Haldar et al. Serological profiles in Indian post kala-azar dermal leishmaniasis
Paul et al. Monoclonal precipitating antibodies to porcine immunoglobulin M
Petersson et al. Cat-bite-induced Francisella tularensis infection with a false-positive serological reaction for Bartonella quintana
CN114989295B (zh) 抗MERS-CoV单克隆抗体及其应用
CN1952137A (zh) 人促甲状腺素受体胞外区氨基端基因表达产物及制备方法和该产物在酶免技术中的应用
Cameron et al. Failure of Klebsiella pneumoniae antibodies to cross‐react with peripheral blood mononuclear cells from patients with ankylosing spondylitis
Moroz et al. A hereditary immunoglobulin A abnormality: absence of light-heavy—chain assembly: Study of immunoglobulin synthesis in tonsillar cells
EP1254374B1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
ES2304340T3 (es) Anticuerpos dirigidos contra procalcitonina, su preparacion y uso.
Selter et al. Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases
Nagy Studies on the precipitin content of bovine sera prepared against various biotypes of Brucella abortus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition